Lenvima Approval History
- FDA approved: Yes (First approved February 13th, 2015)
- Brand name: Lenvima
- Generic name: lenvatinib
- Dosage form: Capsules
- Company: Eisai Inc.
- Treatment for: Thyroid Cancer, Renal Cell Carcinoma
Lenvima (lenvatinib) is an oral multiple receptor tyrosine kinase (RTK) inhibitor for the treatment of progressive radioiodine-refractory differentiated thyroid cancer and advanced renal cell carcinoma.
Development History and FDA Approval Process for Lenvima
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.